Other predisposing factors are impaired liver and renal function, previous CNS treatment (e.g., radiotherapy) and alcohol abuse. When necessary the pH is adjusted with hydrochloric acid and/or sodium hydroxide to a pH of 7.4. During pregnancy, cytarabine should only be administrated on strict indication, where the benefits of the drug to the mother should be weighed against possible hazards to the foetus. Protect from light. The human liver apparently detoxifies a substantial fraction of the administered dose. Cytarabine Injection, an antineoplastic, is a sterile isotonic solution for intravenous and subcutaneous use, which contains no preservative and is available in 20 mg/mL (1000 mg/50 mL) Pharmacy Bulk Package. Most common are gastrointestinal undesirable effects. Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily. Only physicians experienced in cancer chemotherapy should use Cytarabine Injection.For induction therapy patients should be treated in a facility with laboratory and supportive resources sufficient to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity.

Pfizer Hospital US has the broadest portfolio of sterile injectable medications in the US and a diverse selection of surgical products. Because cerebrospinal fluid levels of deaminase are low, little conversion to ara-U was observed.Cytarabine injection is capable of obliterating immune responses in man during administration with little or no accompanying toxicity. Not all pack sizes may be marketed. Steady-state plasma digitoxin concentrations did not appear to change. Limited data suggest that the extent of GI absorption of digitoxin is not substantially affected by concomitant administration of combination chemotherapy regimens known to decrease absorption of digoxin. Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase. Use in Pregnancy (Category D) Cytarabine Injection can cause fetal harm when administered to a pregnant woman. Therefore, monitoring of plasma digoxin levels may be indicated in patients receiving similar combination chemotherapy regimens. These reactions include reversible corneal toxicity; cerebral and cerebellar dysfunction, usually reversible; somnolence; convulsion; severe gastrointestinal ulceration including pneumatises cysteroides intestinalis, leading to peritonitis; sepsis and liver abscess; and pulmonary oedema. Results from one hour infusions have been satisfactory in the majority of patients.Evidence of bone marrow improvement has been reported to occur 7-64 days after the beginning of therapy.In general, if a patient shows neither remission nor toxicity after a trial period, then cautiously administered higher doses can be administered. Each mL contains 100 mg Cytarabine (100 mg/mL) in a 20 mL single dose vial (2 g/20 mL). It is a cell cycle specific antineoplastic drug.Oral administration is ineffective due to rapid deamination in the gut.

12 Neurotoxicity (8-10%) typically occurs 3-8 days after initiating therapy. Educational materials to help empower your customers. Healthcare professionals are asked to report any suspected adverse reactions via: Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App StoreThere is no specific antidote for cytarabine overdose. General information. bone marrow aplasia), unless the benefits outweigh the risk. Therapy should be started cautiously in patients with pre-existing drug-induced bone marrow suppression. The structural formula is:Cytarabine is an odorless, white to off-white crystalline powder which is freely soluble in water and slightly soluble in alcohol and in chloroform.Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture. Cytarabine Injection, an antineoplastic agent, is a sterile preserved solution for intravenous or subcutaneous administration, and is available in a 500 mg (20 mg/mL) multidose vial. This site is provided for educational and informational purposes only, in accordance with our The risk of CNS toxicity increases if the cytarabine treatment -given as high dose i.v.- is combined with another CNS toxic treatment such as radiation therapy or high dose of a cytotoxic agent. Hyperuricemia secondary to rapid lysis of neoplastic cells may occur in patients receiving cytarabine; serum uric acid concentrations should be monitored. Cases of cardiomyopathy with subsequent death have been reported following experimental high dose therapy with cytarabine in combination with cyclophosphamide when used for bone marrow transplant preparation.The safety of the drug has not been established in infants.GI absorption of oral digoxin tablets may be substantially reduced in patients receiving combination chemotherapy regimens (including regimens containing cytarabine), possibly as a result of temporary damage to intestinal mucosa caused by the cytotoxic agents. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia.

Each vial contains approximately 0.58 mEq … What to know about our high quality products. Hospira, Inc., a Pfizer Company Lake Forest, IL 60045 USA US License No. Evidence of bone marrow improvement may be expected 7-64 (mean 28) days after the beginning of treatment.Cytarabine 100 mg/ml Injection is a ready to use injection and can be administered by the intravenous and subcutaneous routes. 2,4,12,22 Continue typing to refine. Physician Prescribing Information; CYTARABINE, Pharmacy Bulk Package Vial U.S.